Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

NCT06629818 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Light Chain (AL) Amyloidosis

Interventions

DRUG: Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)
DRUG: Venetoclax
DRUG: Dexamethasone

Sponsor

Peking Union Medical College Hospital